{
  "segment": [
    {
      "FY": "FY22",
      "period": "2022/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "創薬開発事業",
      "sales": 15406.11,
      "profit": 9179.91,
      "assets": null
    },
    {
      "FY": "FY22",
      "period": "2022/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "放射性医薬品事業",
      "sales": 11446.32,
      "profit": 235.91,
      "assets": null
    },
    {
      "FY": "FY23",
      "period": "2023/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "創薬開発事業",
      "sales": 12702.97,
      "profit": 6387.9,
      "assets": null
    },
    {
      "FY": "FY23",
      "period": "2023/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "放射性医薬品事業",
      "sales": 16009.23,
      "profit": 475.14,
      "assets": null
    },
    {
      "FY": "FY24",
      "period": "2024/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "創薬開発事業",
      "sales": 31313.39,
      "profit": 20957.31,
      "assets": null
    },
    {
      "FY": "FY24",
      "period": "2024/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "放射性医薬品事業",
      "sales": 15363.13,
      "profit": 246.53,
      "assets": null
    },
    {
      "FY": "FY25",
      "period": "2025/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "創薬開発事業",
      "sales": 2793.3,
      "profit": -5358,
      "assets": null
    },
    {
      "FY": "FY25",
      "period": "2025/12",
      "unit": "百万円",
      "accounting_standard": "IFRS",
      "consolidation": "連結",
      "segment": "放射性医薬品事業",
      "sales": 15727.93,
      "profit": 434.8,
      "assets": null
    }
  ]
}